Efficacy and Safety of Valsartan/Amlodipine Combination in Patients With Severe Hypertension

• Status: Completed
• Trial end date: 2005-04-01
• Target enrollment: 0
• Participant gender: All

Summary

This study will assess the effectiveness and safety of different combination antihypertensive treatments in patients with severe hypertension

• Phase: Phase 3

Details

• Lead Sponsor: Novartis
• Treatments: Amlodipine; Valsartan

Criteria

Inclusion Criteria:

• Patients with severe hypertension

Exclusion Criteria:

• History of stroke, myocardial infarction, heart failure, chest pain, abnormal heart rhythm

• Liver, kidney, or pancreas disease

• Insulin dependent diabetes

• Allergy to certain medications used to treat high blood pressure

Other protocol-defined inclusion/exclusion criteria may apply.